RBC Capital Maintains Outperform on ResMed, Raises Price Target to $321

RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $314 to $321.

Transcript: ResMed Q3 2026 Earnings Conference Call

Resmed Appoints Aaron Bloomer CFO, Succeeding Brett Sandercock

Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett Sandercock, Chief Financial Officer, plans to retire effective

ResMed Q3 Adj. EPS $2.86 Beats $2.80 Estimate, Sales $1.431B Beat $1.419B Estimate

ResMed (NYSE:RMD) reported quarterly earnings of $2.86 per share which beat the analyst consensus estimate of $2.80 by 2.14 percent. This is a 20.68 percent increase over earnings of $2.37 per share from the same period

Earnings Scheduled For April 30, 2026

Keybanc Maintains Overweight on ResMed, Lowers Price Target to $290

Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and lowers the price target from $302 to $290.

Citigroup Maintains Buy on ResMed, Lowers Price Target to $340

Citigroup analyst Laura Sutcliffe maintains ResMed (NYSE:RMD) with a Buy and lowers the price target from $345 to $340.